Company / PP&E (Net)
ENANTA PHARMACEUTICALS INC PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$35.4M
FY2025
5-year range
$5.9M / $35.4M
FY2021-FY2025
Trend
+8.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has increased for 4 consecutive years, from $6M in FY2021 to $35M in FY2025.
Based on SEC 10-K filings.
$35M in FY2025 with a 5-year CAGR of +32.7%.
Improved from $12M to $35M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +79.0%
- 5-Year CAGR
- +32.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- ENANTA PHARMACEUTICALS INC's pp&e (net) has grown for 4 consecutive years.
- 5-year CAGR of +32.7%, indicating consistent growth.
- In FY2025, pp&e (net) increased 8.3% year-over-year.
- Lowest pp&e (net) in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $35.4M | +8.3% |
| FY2024 | $32.7M | +174.3% |
| FY2023 | $11.9M | +93.1% |
| FY2022 | $6.2M | +3.9% |
| FY2021 | $5.9M | -30.9% |
| FY2020 | $8.6M | -21.3% |
| FY2019 | $10.9M | +30.5% |
| FY2018 | $8.4M | +4.0% |
| FY2017 | $8.0M | +0.6% |
| FY2016 | $8.0M | +36.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026